Connor, Clark & Lunn Investment Management Ltd. - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.

Quarter-by-quarter ownership
Connor, Clark & Lunn Investment Management Ltd. ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q2 2023$394,360
-53.0%
21,824
-55.3%
0.00%
-60.0%
Q1 2023$838,855
-21.6%
48,799
+1.2%
0.01%
-16.7%
Q4 2022$1,070,47848,1980.01%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q4 2022
NameSharesValueWeighting ↓
Octagon Capital Advisors LP 377,777$15,659,0005.43%
BVF INC/IL 1,106,070$45,847,0001.80%
Eagle Health Investments LP 50,000$2,073,0001.33%
Ally Bridge Group (NY) LLC 150,000$6,218,0001.07%
Casdin Capital, LLC 780,555$32,354,0000.96%
VIKING GLOBAL INVESTORS LP 3,937,914$163,227,0000.45%
Pinz Capital Management, LP 19,900$825,0000.38%
ArrowMark Colorado Holdings LLC 1,063,744$44,092,0000.34%
Perceptive Advisors 600,256$24,881,0000.27%
ACUTA CAPITAL PARTNERS, LLC 20,000$829,0000.23%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders